Where is Precede located?

Precede is headquartered in Boston, United States.

Who is the current CEO of Precede?

Rehan Verjee of Precede. They have also founded 1 company.

How many employees does Precede have?

As of Feb 28, 2026, the latest employee count at Precede is 57.

Is Precede a funded company?

Precede is a funded company, having raised a total of $57M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round.

When was the latest funding round of Precede?

Precede's latest funding was a $***** Series C round on Oct 10, 2023, with participation from 1 investor. Its primary sector is Clinical Genomics. In United States, the Clinical Genomics sector has seen $322M in funding in 2026 to date.

Where does Precede rank among its competitors?

Precede ranks 12th amongst 224 active competitors, of which 83 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was 4baseCare, which secured $9.82M in Jan, 2026.

Who are the top competitors of Precede?

Precede's top competitors include Guardant Health, Personalis and BillionToOne. Among them, 4baseCare secured the most recent funding round in January, 2026.

Precede - 2026 Company Profile, Team, Funding & Competitors

Precede is a series C company based in Boston (United States), founded in 2021 by Rehan Verjee. It operates as a Developer of liquid biopsy platform providing disease-defining biology from blood tests. Precede has raised $57M in funding from investors like 5AM Ventures, Dana Farber and Stealth. The company has 224 active competitors, including 83 funded and 46 that have exited. Its top competitors include companies like Guardant Health, Personalis and BillionToOne.

Company Details

Developer of liquid biopsy platform providing disease-defining biology from blood tests. The platform profiles circulating chromatin and the DNA methylome from plasma. It gives resolution into the dynamic activation of individual genes and pathways. The company partners with developers of new medicines and advances diagnostic tests.

Website: www.precede.bio/
Social
Email ID: *****@precede.bio
Phone Number: +1 **********

Key Metrics

Founded Year

2021

Location

Boston, United States

Stage

Series C

Total Funding

$57M in 3 rounds

Latest Funding Round

Series C, Oct 10, 2023, $*****

Investors

5AM Ventures & 7 more

Ranked

12^th among 224 active competitors

Employee Count

57 as on Feb 28, 2026

Similar Companies

Guardant Health & 218 more

View Precede's full profile

Precede has raised a total funding of $57M over 3 rounds. Its latest funding round was a Series C round on Oct 10, 2023 for $*****. 1 investor participated in its latest round. Precede has 8 institutional investors.

Here is the list of recent funding rounds of Precede:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 10, 2023	6198384	Series C	7978864	7125893	9544442	3647344

Access funding benchmarks and valuations. Sign up today!

View details of Precede's funding rounds and investors

The founders of Precede is Rehan Verjee. Rehan Verjee is the CEO of Precede.

Here are the details of Precede's key team members:

Rehan Verjee: Co-Founder & CEO of Precede.

View details of Precede's Founder profiles and Board Members

Precede's employee count trend

Precede has 57 employees as of Feb 26. Here is Precede's employee count trend over the years:

Uncover Precede's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Precede include Guardant Health, Personalis and BillionToOne. Here is the list of Top 10 competitors of Precede, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Lightspeed Venture Partners ... & 24 others	79/100
2nd	Personalis 2011, Menlo Park (United States), Public	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Lightspeed Venture Partners, Abingworth & 4 others	70/100
3rd	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 29 others	69/100
4th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	DFJ Growth, Merck Global Health Innovation Fund ... & 19 others	68/100
5th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Civilization Ventures & 6 others	66/100
6th	Scipher Medicine 2014, Waltham (United States), Series D	Provider of precision medicine based on liquid biopsy test	$233M	Northpond Ventures, Cowen & 14 others	65/100
7th	4baseCare 2018, Bengaluru (India), Series B	Provider of precision oncology solutions, including genomic testing and digital health	$22.3M	Tremis Consultancy, Yali Capital & 55 others	63/100
8th	Ultivue 2015, Cambridge (United States), Series D	Provider of test panels for personalized cancer therapies	$105M	Northpond Ventures, Arch Venture Partners ... & 7 others	63/100
9th	ACT Genomics 2014, Taipei (Taiwan), Acquired	Clinical and research services in genomics for cancer	$20.5M	Hotung Investment Holdings, CLSA Capital Partners ... & 9 others	62/100
10th	Saga Diagnostics 2016, Lund (Sweden), Acquired	Provider of tests for detection and analysis of circulating tumor DNA	$17.9M	Hadean Ventures, Segulah Medical Acceleration ... & 11 others	62/100
12th	Precede 2021, Boston (United States), Series C	Developer of liquid biopsy platform providing disease-defining biology from blood tests	$57M	Qatar Investment Authority, Bristol-Myers Squibb ... & 6 others	60/100